Posted by Michael Wonder on 11 Aug 2018
Castle Creek Pharmaceuticals receives FDA fast track designation for diacerein 1% ointment for treatment of epidermolysis bullosa simplex
9 August 2018 - Biopharmaceutical company currently evaluating diacerein 1% ointment in ongoing DELIVERS study.
Castle Creek Pharmaceuticals, LLC., a US-based company dedicated to delivering transformative therapies to patients with orphan dermatologic and other underserved conditions, today announced that the U.S. FDA has designated as a fast frack development program the investigation of diacerein 1%, ointment for the treatment of epidermolysis bullosa simplex.
The FDA previously granted orphan drug designation and rare paediatric Disease eligibility to CCP-020 for the treatment of epidermolysis bullosa.
